Fintel on MSN11h
HC Wainwright & Co. Initiates Coverage of Kairos Pharma (KAPA) with Buy Recommendation
Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...
H.C. Wainwright Keeps Their Hold Rating on Ryvyl (RVYL)
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Ryvyl (RVYL – Research Report) today. The company’s shares closed yesterday at ...
HC Wainwright Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...
Rezolve AI (NASDAQ:RZLV) Coverage Initiated by Analysts at HC Wainwright
Investment analysts at HC Wainwright began coverage on shares of Rezolve AI (NASDAQ:RZLV – Get Free Report) in a research ...
Fintel on MSN1d
HC Wainwright & Co. Upgrades Sarepta Therapeutics (SRPT)
Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...
Kalkine Media1d
Could HC Wainwright's Appraisal Backfire on Cabaletta Bio?
Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...
Kairos Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $12 price target The company’s oncology pipeline “could ...
Kalkine Media1d
Vanda Pharmaceuticals (NASDAQ:VNDA) has been given a Buy rating by HC Wainwright.
Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...
Investing7d
Nektar at H.C. Wainwright Conference: Strategic Updates on Respegg Trials
On Thursday, 27 March 2025, Nektar Therapeutics (NASDAQ: NKTR) participated in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company provided a strategic ...
Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...
Investing7d
Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases
Aclaris boasts a cash balance exceeding $200 million, ensuring financial stability until 2028. The company plans significant pipeline developments, including IND submissions and clinical data ...